BioLive Wire · AI-collected

BioNTech Drops 10% on mRNA Trial Failure, Highlighting Moderna Contrast

By VERITAS TICKER Desk · Published Aug 28Source: Investing.com ↗

3-line summary

BioNTech shares dropped 10% on an mRNA trial failure, highlighting a contrast with Moderna, according to Investing.com.

This summary is our own processing of the source article; see the source link below for full context.